Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Trial Profile

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2009

At a glance

  • Drugs Anecortave (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2007 Status changed from recruiting to discontinued.
    • 17 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top